A new worldwide study of an oral drug for patients with BCC that is either extensive or spreading (metastatic) is now open in the the UK.

It will assess the effectiveness and safety of a new oral drug called LDE225, in these patients. To be eligible patients need to either have a BCC that has spread within their bodies or have a BCC greter than 1.5 cm, which is felt to be untreatable by other therapies such as surgery or radiotherapy.  It is open for patients with or without Gorlin Syndrome. The study hopes to recruit 120 patients worldwide and patients selected will be allocted to receive one of two possible drug stengths of LDE225. 

If you would like further information then click here  

Details of all investigation sites are listed, so just scroll down the list to see just where the study is available.